SCHEMBL1633121

SCHEMBL1633121

NS(=O)(=O)c1ccc(Nc2ncc3cccc(-c4ccc(NCCN5CCOCC5)nc4)c3n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 5/20 0.52
JUN P05412 3/20 0.47
MAPK8 P45983 3/20 0.47
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA9 Q16790 4/20 0.46
JAK2 O60674 1/20 0.45
TBK1 Q9UHD2 3/20 0.45
CSF1R P07333 2/20 0.45
TYK2 P29597 2/20 0.45
NTRK1 P04629 2/20 0.45
NUAK1 O60285 1/20 0.45
STK16 O75716 1/20 0.45
CSNK2A2 P19784 1/20 0.45
AAK1 Q2M2I8 1/20 0.45
ULK3 Q6PHR2 1/20 0.45
BMP2K Q9NSY1 1/20 0.45
PLK1 P53350 1/20 0.45
ULK2 Q8IYT8 1/20 0.45
FYN P06241 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633149 0.93 CA1 (0.48) MAPK10CA1CA2CA9JAK2
SCHEMBL1631590 0.88 MAPK10 (0.50) MAPK10JUNMAPK8PLK1FYN
SCHEMBL1634792 0.88 MAPK10 (0.43) MAPK10CA1CA2CA9JAK2
SCHEMBL1633488 0.85 MAPK10 (0.56) MAPK10JUNMAPK8JAK2NTRK1
SCHEMBL1632922 0.84 JAK2 (0.48) MAPK10JUNMAPK8JAK2FGFR2
SCHEMBL1633928 0.83 MAPK10 (0.69) MAPK10JUNMAPK8JAK2TYK2
SCHEMBL1634316 0.83 TBK1 (0.57) MAPK10JUNMAPK8CA1CA2
SCHEMBL1633630 0.82 MAPK10 (0.45) MAPK10JUNMAPK8FYNFGFR2
SCHEMBL1633868 0.82 MAPK10 (0.57) MAPK10JUNMAPK8CA1CA2
SCHEMBL13498354 0.82 MAPK10 (0.49) MAPK10JUNCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 MAPK10 402/4885JUN 544/4885MAPK8 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.